Sonora Investment Management Group LLC Has $17.88 Million Stock Holdings in Johnson & Johnson (NYSE:JNJ)

Sonora Investment Management Group LLC increased its stake in shares of Johnson & Johnson (NYSE:JNJ - Free Report) by 2.5% during the 1st quarter, according to its most recent disclosure with the SEC. The institutional investor owned 107,836 shares of the company's stock after acquiring an additional 2,666 shares during the period. Johnson & Johnson comprises approximately 1.4% of Sonora Investment Management Group LLC's investment portfolio, making the stock its 22nd largest holding. Sonora Investment Management Group LLC's holdings in Johnson & Johnson were worth $17,884,000 as of its most recent SEC filing.

A number of other hedge funds have also recently bought and sold shares of the stock. WealthTrak Capital Management LLC acquired a new stake in Johnson & Johnson during the 4th quarter valued at $26,000. Mountain Hill Investment Partners Corp. bought a new stake in shares of Johnson & Johnson in the fourth quarter valued at about $29,000. Conquis Financial LLC acquired a new position in shares of Johnson & Johnson in the fourth quarter valued at about $33,000. Bernard Wealth Management Corp. bought a new stake in Johnson & Johnson in the 4th quarter valued at about $36,000. Finally, Runnymede Capital Advisors Inc. acquired a new position in shares of Johnson & Johnson during the 4th quarter worth approximately $38,000. 69.55% of the stock is currently owned by institutional investors.

Johnson & Johnson Price Performance

JNJ stock traded down $1.26 during midday trading on Wednesday, reaching $155.19. 6,007,883 shares of the stock were exchanged, compared to its average volume of 7,935,976. Johnson & Johnson has a 52 week low of $140.68 and a 52 week high of $169.99. The company has a fifty day moving average price of $153.52 and a 200 day moving average price of $153.69. The company has a debt-to-equity ratio of 0.43, a current ratio of 1.11 and a quick ratio of 0.86. The stock has a market capitalization of $373.41 billion, a PE ratio of 23.34, a P/E/G ratio of 2.56 and a beta of 0.42.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last released its quarterly earnings data on Tuesday, April 15th. The company reported $2.77 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.59 by $0.18. Johnson & Johnson had a return on equity of 34.24% and a net margin of 18.20%. The company had revenue of $21.89 billion during the quarter, compared to the consensus estimate of $21.65 billion. As a group, analysts expect that Johnson & Johnson will post 10.58 EPS for the current fiscal year.

Johnson & Johnson Increases Dividend

The firm also recently declared a quarterly dividend, which was paid on Tuesday, June 10th. Stockholders of record on Tuesday, May 27th were issued a dividend of $1.30 per share. This represents a $5.20 dividend on an annualized basis and a dividend yield of 3.35%. The ex-dividend date was Tuesday, May 27th. This is a positive change from Johnson & Johnson's previous quarterly dividend of $1.24. Johnson & Johnson's payout ratio is 57.84%.

Wall Street Analysts Forecast Growth

A number of research firms have recently weighed in on JNJ. Wall Street Zen downgraded shares of Johnson & Johnson from a "strong-buy" rating to a "buy" rating in a research report on Thursday, May 22nd. Morgan Stanley lifted their price objective on Johnson & Johnson from $164.00 to $169.00 and gave the company an "equal weight" rating in a report on Wednesday, April 16th. Guggenheim reissued a "neutral" rating on shares of Johnson & Johnson in a report on Wednesday, April 2nd. Benchmark upgraded Johnson & Johnson to a "strong-buy" rating in a research report on Thursday, April 24th. Finally, Raymond James cut their price objective on shares of Johnson & Johnson from $165.00 to $162.00 and set an "outperform" rating for the company in a research report on Monday, April 14th. Eleven analysts have rated the stock with a hold rating, eight have assigned a buy rating and two have issued a strong buy rating to the company's stock. According to MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $170.88.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.